For US Healthcare Professionals Only

Cumulative in vitro inhibition of P aeruginosa*†

  • The chart below highlights the cumulative percent of P aeruginosa isolates inhibited at each MIC for DORIBAX® and meropenem (from TRUST 13)1:
DORIBAX® – Cumulative in vitro inhibition of P aeruginosa

In TRUST 13 (2009), surveillance studies supported by Janssen Pharmaceuticals, Inc., P aeruginosa isolates (n=1215) were collected from 65 geographically distributed sites in the US and tested against DORIBAX® and several other antibacterials.1

DORIBAX® – Cumulative in vitro inhibition of P aeruginosa

*In vitro activity does not necessarily correlate with clinical results; not intended to convey comparative safety or efficacy.

† FDA susceptible breakpoint: DORIBAX®, MIC ≤2 µg/mL; meropenem,
MIC ≤4 µg/mL.2

Explore more about DORIBAX® and the consistently low MIC90 against
P aeruginosa from a multi-year surveillance program.

Please see Select Usage Information below.

References



 

Select Usage Information

 

  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy